OSTX (OS Therapies) Moat Score: 2/10 (As of Jul. 27, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTX OS Therapies Inc OSTX
10 GF Score
Price $1.54
! 4 Warning Signs
View Full Analysis

What is OS Therapies Moat Score?

OS Therapies OSTX +0.99% 10 Moat Score is 2 as of Jul. 27, 2026. GuruFocus rates OSTX with a GF Score™ of 10/100. The stock has 4 warning signs investors should review. Among 1,393 Biotechnology companies, OS Therapies ranks better than 58.29% on this metric.

OS Therapies has the Moat Score of 2, which implies that the company might have No Moat - Very weak/transient advantages.

OS Therapies has No Moat: OS Therapies Inc lacks significant market leadership or proprietary technology. The company does not exhibit strong brand strength, customer loyalty, or regulatory barriers. Its competitive advantages are weak and transient, with no clear evidence of durable cost advantages or significant intellectual property.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes OS Therapies might have No Moat - Very weak/transient advantages.

OS Therapies  (AMEX:OSTX) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

OS Therapies Moat Score Related Terms

OSTX vs RNTX, BSEM, PLRX: Moat Score Comparison

For the Biotechnology subindustry, OS Therapies's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

OS Therapies Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OS Therapies's Moat Score distribution charts can be found below:

* The bar in red indicates where OS Therapies's Moat Score falls into.


OSTX
10GF Score
OS Therapies Inc OSTX
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 2 mean?
OS Therapies (OSTX) has a Moat Score of 2 as of Jul. 27, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, OS Therapies ranks #581 out of 1393 companies in the Biotechnology industry, placing it in the top 41.7%.
Is OS Therapies' Moat Score too high?
OS Therapies' current Moat Score is 2. The Biotechnology industry median Moat Score is 2.00. OS Therapies' value of 2 is 0% at this industry median. Based on the distribution chart, OS Therapies ranks #581 out of 1393 companies in the Biotechnology industry, which is above the industry midpoint. Overall, OS Therapies has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does OS Therapies' Moat Score compare to RNTX and BSEM?
According to the Biotechnology industry distribution chart, OS Therapies ranks #581 out of 1393 companies for Moat Score. This puts OS Therapies in the upper half of its industry. The industry median Moat Score is 2.00. OS Therapies' value of 2 is 0% at this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,393 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. OS Therapies's current Moat Score of 2 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. OS Therapies's current Moat Score is 2. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OS Therapies stock overvalued right now?
OS Therapies (OSTX) has a current Moat Score of 2. The current Moat Score is 2 and 0% at the Biotechnology industry median of 2.00. OS Therapies' overall GF Score™ is 10/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For OS Therapies (OSTX), the current Moat Score is 2 as of Jul. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

OS Therapies Business Description

Address 115 Pullman Crossing Road, Suite 103, Grasonville, MD, USA, 21638
OS Therapies Inc is a clinical stage biopharmaceutical company focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. The company's mission is to address the need for new treatments in cancers of the bone in children and young adults. The company has pipeline of product candidates targeting multiple indications for solid cancers including two drug technologies: (i) OST-HER2, an off-the-shelf immunotherapy, which is a type of cancer treatment that helps the immune system fight cancer and OST-tADC which is a tunable drug conjugate (tADC) platform currently in preclinical development. Each tADC contains four main components: ligand, payload cassette adaptor, linker and payload.
10GF Score

Get the complete analysis for OSTX

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.54
Price